Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | TILs prolong PFS compared with pembrolizumab in advanced melanoma

Sebastian Kobold, MD, PhD, Ludwig-Maximilians-Universität München, Munich, Germany, provides an overview of his highlight of the European Society for Medical Oncology (ESMO) 2022 Congress. Data was presented on the Phase III TIL (NCT02278887) trial, which compared tumor infiltrating lymphocytes (TIL) to standard ipilimumab in patients with metastatic melanoma. The trial met its primary endpoint of progression-free survival (PFS), demonstrating a median PFS of 7.2 months versus 3.1 months with the treatment of TILs versus pembrolizumab, respectively. This was the first clinical trial to show randomized efficacy of TILs in this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.